Enveda is a drug discovery analytics company valued at $1.2 billion following its $150 million Series D, according to Pitchbook. Founded in 2019, the company has raised $520 million to date from investors including Lux Capital and True Ventures. Enveda uses advanced computational and biological data platforms to accelerate molecule discovery and improve drug development outcomes. With strong backing and rapid funding momentum, the company is positioned for continued growth in the biotech and pharmaceutical innovation space.